STIP1 Tissue Expression Is Associated with Survival in Chemotherapy-Treated Bladder Cancer Patients

U. Krafft, S. Tschirdewahn, J. Hess, N. N. Harke, B. A. Hadaschik, P. Nyírády, A. Szendröi, M. Szücs, O. Módos, C. Olah, E. Székely, H. Reis, Tibor Szarvas

Research output: Contribution to journalArticle

Abstract

To optimize treatment decisions in advanced bladder cancer (BC), we aimed to assess the therapy predictive value of STIP1 with regard to cisplatin therapy. Cisplatin-based chemotherapy represents the standard first-line systemic treatment of advanced bladder cancer. Since novel immunooncologic agents are already available for cisplatin-resistant or ineligible patients, biological markers are needed for the prediction of cisplatin resistance. STIP1 expression was analyzed in paraffin-embedded bladder cancer tissue samples of 98 patients who underwent adjuvant or salvage cisplatin-based chemotherapy by using immunohistochemistry. Furthermore, pre-chemotherapy serum STIP1 concentrations were determined in 48 BC patients by ELISA. Results were correlated with the clinicopathological and follow-up data. Stronger STIP1 nuclear staining was associated with worse OS in both the whole patient group (p = 0.034) and the subgroup of patients who received at least 2 cycles of chemotherapy (p = 0.043). These correlations remained significant also in the multivariable analyses (p = 0.035 and p = 0.040). Stronger STIP1 cytoplasmatic immunostaining correlated with shorter PFS both in the whole cohort (p = 0.045) and in the subgroup of patients who received at least 2 cycles of chemotherapy (p = 0.026). Elevated STIP1 serum levels were associated with older patient’s age, but we found no correlation between STIP1 serum levels and patients’ outcome. Our results suggest that tissue STIP1 analysis might be used for the prediction of cisplatin-resistance in BC. In contrast, pretreatment STIP1 serum levels showed no predictive value for chemotherapy response and survival.

Original languageEnglish
JournalPathology and Oncology Research
DOIs
Publication statusPublished - Jan 1 2019

    Fingerprint

Keywords

  • Bladder cancer
  • Cisplatin
  • Resistance
  • STIP1

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Oncology
  • Cancer Research

Cite this

Krafft, U., Tschirdewahn, S., Hess, J., Harke, N. N., Hadaschik, B. A., Nyírády, P., Szendröi, A., Szücs, M., Módos, O., Olah, C., Székely, E., Reis, H., & Szarvas, T. (2019). STIP1 Tissue Expression Is Associated with Survival in Chemotherapy-Treated Bladder Cancer Patients. Pathology and Oncology Research. https://doi.org/10.1007/s12253-019-00689-y